Category Archives: Healthcare

Chardan Capital Believes Arbutus Biopharma Corporation (NASDAQ: ABUS) Still Has Room to Grow

Chardan Capital analyst Keay Nakae maintained a Buy rating on Arbutus Biopharma Corporation (NASDAQ: ABUS) on July 11 and set a price target of $11. The company’s shares closed on Friday at $11.70, close to its 52-week high of $12.05.

H.C. Wainwright Remains a Buy on Foamix Pharma

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Foamix Pharma (NASDAQ: FOMX), with a price target of $12. The company’s shares closed on Friday at $5.80. According to TipRanks.com, Selvaraju is a 3-star

Adamas Pharmaceuticals Receives a Buy from H.C. Wainwright

Adamas Pharmaceuticals (NASDAQ: ADMS) received a Buy rating and a $45 price target from H.C. Wainwright analyst Ram Selvaraju today. The company’s shares closed on Friday at $27.06. Selvaraju commented: “Valuation methodology, risks and uncertainties. We have utilized a discounted

H.C. Wainwright Thinks Sol-Gel Technologies Ltd’s Stock is Going to Recover

In a report released today, Ram Selvaraju from H.C. Wainwright initiated coverage with a Buy rating on Sol-Gel Technologies Ltd (NASDAQ: SLGL) and a price target of $21. The company’s shares closed on Friday at $6.97, close to its 52-week

Morgan Stanley Remains a Hold on Celgene

Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Celgene (NASDAQ: CELG) on July 13 and set a price target of $91. The company’s shares closed on Friday at $85.69, close to its 52-week low of $74.13. According to

Morgan Stanley Believes Amgen Inc (NASDAQ: AMGN) Still Has Room to Grow

In a report issued on July 13, Matthew Harrison from Morgan Stanley maintained a Buy rating on Amgen Inc (NASDAQ: AMGN), with a price target of $210. The company’s shares closed on Friday at $195.91, close to its 52-week high